StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$398.08−23.91 (-5.67%)

Close on Nov 18, 2026Market cap $9.20BP/E –Yield –

Madrigal Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Madrigal Pharmaceuticals's price to sales ratio was 7.8× on Nov 11, 2026, against 18.3× a year earlier. Over the last 2 years it ranged from 7.7× to 352.1×, with a median of 18.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.8×−10.1
2025Dec 31, 202517.9×−69.7
2024Dec 31, 202487.6×–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?